Printer-friendly version

Despite improvements in two provinces, in Canada as a whole, waiting time for surgical and other therapeutic treatments remained long in 1999.

Printer-friendly version

Risk regulation as it is currently implemented has many pitfalls. In some cases, regulations to address one risk can introduce other risks. In many cases, expenditure to reduce a risk could save many more years of life if spent reducing another risk. These issues are not currently considered by many of the interest groups calling for more risk regulation, the public supporting those calls, or the governments who respond by introducing more regulation. Instead, risk activists and regulators focus on the potential benefits of risk regulation while ignoring the costs.

Printer-friendly version

This study compares the prices of prescription drugs in Canada and the United States. The measure used is the replacement cost, at Canadian prices, of drugs consumed by the average American pharmacy or consumer. The sample was selected from the drugs consumed in the largest quantities in the United States. This ensures that the study captured non-patented as well as patented drugs.

Printer-friendly version

This study compares the prices of prescription drugs in Canada and the United States. The measure used is the replacement cost, at Canadian prices, of drugs consumed by the average American pharmacy or consumer. The sample was selected from the drugs consumed in the largest quantities in the United States. This ensures that the study captured non-patented as well as patented drugs.

Printer-friendly version

Of the several amendments that have been made to the Canadian Constitution over the years that directly affect provincial interests, all but one have been achieved as a result of extensive negotiations between the federal and provincial governments.

Printer-friendly version

The national significance of Delgamuukw case prompted the Fraser Institute to hold two conferences on the issue, the first in Vancouver in July 1998 and a second and larger one in Ottawa in April 1999. This book contains the papers and proceedings of those two events.

Printer-friendly version

Throughout North America, governments--federal, provincial, state, and local--have declared tobacco to be public health enemy Number 1. What should public policy be toward tobacco, a legal product that remains a habitual pleasure for one Canadian in four? To answer this question, The Fraser Institute invited leading scientists, public-policy experts, and journalists to meet in Ottawa on May 13, 1999 to debate the costs and benefits of tobacco regulation.

This seminal event produced several important critiques of past and present government policies towards both the companies that produce tobacco products and the consumers of these products. This publication is the first of a number of Public Policy Sources highlighting specific aspects of the debate over tobacco regulation.